Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcriptional and immune response regulator (TCIM)
- Target
- TCIM
- Molecular classification
- Other (small, unstructured protein, not a classical receptor, enzyme, or transporter)
01
Overview
Transcriptional and immune response regulator (TCIM, abbreviated as TCIM; also known as C8orf4, TC1, thyroid cancer protein 1) encodes a small, monomeric, mainly unstructured protein. TCIM serves as a positive regulator of the Wnt/beta-catenin signaling pathway, primarily by antagonizing the repressive effects of CBY1 and upregulating downstream beta-catenin target genes. It is implicated in cell growth, differentiation, proliferation, and the transition from G1 to S phase of the cell cycle. TCIM also modulates NF-kappaB and ERK1/2 pathways, enhances inflammatory responses, and participates in heat-shock responses. Expression of TCIM is associated with cancer progression in several malignancies (notably thyroid, breast, and lung), but it can have opposite effects in different tissues. There are currently no clinically approved drugs that target TCIM directly, and its roles in disease and cell physiology remain an active area of research
- Other names
- C8orf4TC1TC-1hTC-1Thyroid cancer protein 1Human thyroid cancer 1Protein C8orf4
02
Mechanism of action
Not established directly; potential mechanisms may involve modulation of Wnt/beta-catenin, NF-kappaB, ERK1/2 pathways if targeted
03
Biological functions
Positive regulation of Wnt/beta-catenin signaling pathwayRegulation of cell growth and differentiationEnhancement of WNT–CTNNB1 pathway by antagonizing CBY1Regulation of NF-kappaB and ERK1/2 signaling pathwaysEnhancement of proliferation of follicular dendritic cellsPositive regulation of G1-to-S-phase cell cycle transitionModulation of inflammatory responseRegulation of heat shock response via HSF1 feedbackInhibition of apoptosis (in cancer cells)Regulation of hematopoiesis
04
Disease associations
Cancer (thyroid cancer, breast cancer, lung cancer, hematological malignancies, squamous cell carcinoma of the tongue)InflammationHypertrichosis universalis congenita, Ambras type (minor association)
05
Safety considerations
Safety and therapeutic concerns not established, as no direct drugs target TCIMPotential challenges include tissue-specific effects and paradoxical roles in different cell types (e.g., can promote cancer proliferation, can inhibit self-renewal in liver cancer cells)
06
Biomarkers
TCIM/C8orf4 expression may correlate with cancer progression (e.g., sq. cell carcinoma of tongue, thyroid, breast, and lung cancers); not established as a routine clinical biomarker
Beyond the preview
Go deeper on Transcriptional and immune response regulator (TCIM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcriptional and immune response regulator (TCIM).